Category: WFN1 Contributors

1 2 3 79 10 / 784 POSTS
By David Bautz, PhDNASDAQ:VKTXREAD THE FULL VKTX RESEARCH REPORTBusiness UpdateNo Cardiovascular Toxicity Concerns for VK2809Following release of the Phase 2 data for VK2809 in patients with hypercholesterolemia and nonalcoholic fatty liver disease ( ...
By Brian Marckx, CFANASDAQ:GNMXREAD THE FULL GNMX RESEARCH REPORTASCEND Misses Primary Endpoint: GNMX indicates they are not giving up in AEVI-001On January 2nd Aevi (NASDAQ:GNMX) announced that ASCEND, the phase II trial evaluating their non-stimula ...
By Brian Marckx, CFANASDAQ:BMRAREAD THE FULL BMRA RESEARCH REPORTBiomerica’s IgG Antibody Test Used to Significantly Reduce Ulcerative Colitis Symptoms, Improve QoLResults of an n=97 randomized, investigator-blinded food-exclusion study showed that B ...
By Brian Marckx, CFANASDAQ:NAOVREAD THE FULL NAOV RESEARCH REPORTZacks SCR Senior Med-Tech analyst and Director of Research Brian Marckx, CFA has initiated coverage of NanoVibronix, Inc. with a $9.00/share price target. See below for free access to h ...
By Anita Dushyanth, PhDNYSE:NNVCREAD THE FULL NNVC RESEARCH REPORTINITIATING COVERAGENanoViricides, Inc. (NYSE:NNVC) is an early stage nano-pharmaceutical company that was first listed in 2005 and became a reporting company the following year. The co ...
By David Bautz, PhDTSX:ATE.VREAD THE FULL ATE.V RESEARCH REPORTFinancial UpdateOn December 19, 2018, Antibe Therapeutics, Inc. (TSX:ATE.V) announced a warrant exercise of nearly all outstanding warrants with an expiration date in December 2018 that r ...
By Brian Marckx, CFANASDAQ:DRRXREAD THE FULL DRRX RESEARCH REPORTPipeline UpdateEarlier this week Durect (NASDAQ:DRRX) provided a corporate and pipeline update. Much of the focus was, as expected, on DUR-928. Particularly noteworthy is that the compa ...
By David Bautz, PhDNASDAQ:CFRXREAD THE FULL CFRX RESEARCH REPORTBusiness UpdateTreatment with Exebacase Beneficial to S. Aureus Bacteremia Patients On January 7, 2019, ContraFect Corp. (NASDAQ:CFRX) announced topline results from the Phase 2 trial of ...
By David Bautz, PhDNASDAQ:BCLIREAD THE FULL BCLI RESEARCH REPORTBusiness UpdateSet to Initiate Phase 2 Trial in Progressive MSOn December 17, 2018, BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) announced that the U.S. Food and Drug Administration ...
what we did in Turbo Trading... bit.ly/2UQGJms @stewdomer 4h4 hours ago More Short AXGN at $20.55. Target $19...10:25 AM @stewdomer 4h4 hours ago More $KTOV we had small trade In $1.22 / OUT $1.34 no home runs today ...
1 2 3 79 10 / 784 POSTS